Last reviewed · How we verify
Ipilimumab Injection
Ipilimumab blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.
Ipilimumab blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses. Used for Metastatic melanoma, Advanced or metastatic colorectal cancer (in combination with nivolumab), Metastatic non-small cell lung cancer (in combination with nivolumab).
At a glance
| Generic name | Ipilimumab Injection |
|---|---|
| Also known as | Atezolizumab, Bevacizumab, Yervoy, BMS-734016, MDX010 |
| Sponsor | Federation Francophone de Cancerologie Digestive |
| Drug class | CTLA-4 inhibitor |
| Target | CTLA-4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ipilimumab is a monoclonal antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a negative regulator of T-cell activation. By blocking CTLA-4, the drug removes a 'brake' on the immune system, allowing T cells to become more activated and proliferate. This enhanced immune activation enables the body's own immune cells to recognize and attack cancer cells more effectively.
Approved indications
- Metastatic melanoma
- Advanced or metastatic colorectal cancer (in combination with nivolumab)
- Metastatic non-small cell lung cancer (in combination with nivolumab)
Common side effects
- Immune-related colitis
- Immune-related hepatitis
- Immune-related pneumonitis
- Immune-related endocrinopathy (thyroiditis, hypophysitis)
- Rash
- Fatigue
- Diarrhea
Key clinical trials
- Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (PHASE2, PHASE3)
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (PHASE1, PHASE2)
- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) (PHASE1)
- XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer (NA)
- Neo-adjuvant Immunotherapy in Patients With Localized Melanoma (PHASE2)
- CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (PHASE1)
- Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ipilimumab Injection CI brief — competitive landscape report
- Ipilimumab Injection updates RSS · CI watch RSS
- Federation Francophone de Cancerologie Digestive portfolio CI